Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ib-Meca SCHEMBL12265127 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29572081 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29634441 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL465039 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL448115 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL10089200 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29384499 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL8922766 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL20905217 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29762168 | 0.94 | ADORA3 (0.89) | ADORA3ADORA1CYP3A4MAPK1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-15 | — | — | US | disclosed |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| WO-2017052322-A1 | ADENOSINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENT | 퓨쳐메디신 주식회사 | 2017-03-30 | — | — | WO | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011143442-A1 | A METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | TROVIS PHARMACEUTICALS, LLC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2009089425-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | PGXHEALTH LLC (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181920-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2008124150-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | PDE4A, ADORA2A, PDE4B | ADORA3 13/4885ADORA1 18/4885CYP3A4 1470/4885 |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ADORA1 4/4885CYP3A4 1273/4885 |
| US-20090181920-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885CYP3A4 4082/4885 |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ADORA1 4/4885CYP3A4 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.